There is more trouble for Ranbaxy, this time from the European Union. The new headache for India's largest pharmaceutical company comes as it battles a huge credibility crisis after being fined $500 million by the United States for selling sub-standard drugs and faking quality tests. It is a huge blow to Ranbaxy, but more importantly, has raised serious concerns about the quality of the company's other drugs and whether we are safe.
